Celcuity (CELC) has been in focus after the FDA accepted its New Drug Application for gedatolisib with priority review, while management simultaneously accelerates commercial preparation ahead of a potential launch.

The share price has been volatile around these updates, with a 1 day share price return of negative 7.66% and a 30 day share price return of negative 5.09%. However, the 1 year total shareholder return is very large and indicates that longer term momentum has been strong.

If this kind of biotech risk reward profile interests you, it can be useful to see what else is moving in healthcare AI by checking out 34 healthcare AI stocks

With Celcuity still loss making, a value score of 3, an intrinsic value estimate implying a large discount, and the share price below the average analyst target, the key question is whether there is a genuine opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 9.2% Undervalued

Celcuity's most followed narrative pegs fair value at $116.70, a touch above the last close of $106.02. This sets up an interesting gap between price and expectations.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

Want to see what is baked into that fair value? The narrative leans heavily on rapid revenue lift, rising margins and a rich future earnings multiple. The tension between current losses, expected profitability and a premium P/E assumption is at the heart of the story.

Result: Fair Value of $116.70 (UNDERVALUED)

However, this hinges on timely FDA approvals and strong trial outcomes; any delay in commercialization or weaker clinical data could quickly challenge that 9.2% undervalued case.

Another View: Multiples Paint A Different Picture

The first narrative leans on discounted cash flows and future earnings power. Yet today Celcuity trades on a P/B of 51x versus 2.2x for the US Biotechs industry and 16.9x for peers. That rich gap suggests a lot is already in the price, so how comfortable are you with that kind of valuation tension?

Next Steps

Curious whether the optimism or caution in this story matches your own take? Move quickly, review the full picture, and weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

You have already done the work on Celcuity, so now is the moment to widen your watchlist and compare it with other focused opportunities across different angles.

• Hunt for potential bargains with strong fundamentals by scanning 62 high quality undervalued stocks before others spot them.
• Prioritize strength and resilience by reviewing companies in the solid balance sheet and fundamentals stocks screener (39 results) so your shortlist starts from financial stability.
• Get ahead of the crowd by uncovering under followed opportunities through the screener containing 25 high quality undiscovered gems that most investors are not watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.